Cell Surgical Network Competitors

Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. Amgen is one of 30 companies comprising the Dow Jones Industrial Average®, and part of the Nasdaq-100 Index®. In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes. For more information, visit Amgen.com and follow us on X, LinkedIn, Instagram, TikTok, YouTube and Threads. 🔗 Community Guidelines: https://wwwext.amgen.com/community-guidelines 🔗Global Privacy Statement Directory: www.amgen.com/dp Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.

At Revolution Medicines, we aim to change the trajectory of disease for patients living with RAS-addicted cancers around the world. We challenge assumptions, act on what the science reveals, and push beyond convention to tackle some of the most difficult-to-treat cancers. Our differentiated, platform-driven approach targets RAS in its active, ON state—unlocking a fundamentally new way to inhibit RAS. We are advancing a broad, integrated pipeline of inhibitors with the ambition to establish RAS(ON) inhibition as the backbone for treating RAS-addicted cancers while continuing to pioneer the next generation of innovation. We follow the science and act on it with urgency to turn insights into new treatments—because for patients, the stakes are deeply personal, measured in time and quality of life. For additional information on our guidelines, please visit https://www.revmed.com/social-media-community-guidelines/

Organogenesis™ is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care.